Dr. Gulshan Sharma Discusses the Hospitalist Movement
In this video, Gulshan Sharma, MD, MPH, Associate Professor, University of Texas Medical Branch, Galveston, TX, addresses the hospitalist movement, which has resulted in shorter hospital stays and lower costs of care. Regarding hospitalist physicians Dr Sharma says that, "they have done a tremendous job of improving the efficiency and quality of care in the United States." Hospitalist leadership has incorporated many new initiatives to improve care transition processes. Dr Sharma says that the BOOST system is one of the most important processes to that aim to reduce readmissions.
This video was taken on May 19, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
From Medicaid providers that are regulated as insurers alongside managed care organizations, as happens in Mississippi, to “enhanced medical homes,” which are found in Colorado, the variety that exists in healthcare delivery across the states has adapted to reflect the shift to accountable care, according to an author writing for the American Journal of Public Health.
Panelists discussed the price of pharmaceuticals and controlling the cost of care at the 64th Annual Roy A. Bowers Pharmaceutical Conference: A Measured Approach—Health Care Delivery and Transformation in a Metric Driven World, held by Rutgers University.
From the youngest patients to the oldest, the Affordable Care Act’s promise that care will be provided despite pre-existing conditions is bumping against the challenge of keeping costs in check. From around the country come reports of pushback, which evoke the 1990s stories of managed care’s debut: limited choice.
The era of accountable care and pay for performance is here, and physicians will have to embrace these novel reimbursement models. In a plenary session, Rubin Cohen, MD, FCCP, a member of the American College of Chest Physician’s quality improvement committee, discussed the relationship between quality improvement and outcomes.
A symposium on idiopathic pulmonary fibrosis (IPF), which was presented on behalf of InterMune, Inc, highlighted clinical data supporting the use of pirfenidone in patients with IPF. Leading the panel discussion was Steven Nathan, MD, FCCP, a principal investigator involved in studies of pirfenidone. Dr Nathan was joined by IPF experts Lisa Lancaster, MD, of Vanderbilt University Medical Center and Marilyn Glassberg, MD, of the University of Miami Health System.